Dermatology Dialogues
Oral povorcitinib promising in extensive nonsegmental vitiligo at week 52 in Phase 2b clinical trial
Latest News and Guidelines
JAK inhibitor use in skin conditions associated with elevated odds of the appearance of acne: JAMA
Guselkumab efficacious among patients of psoriasis with skin of color
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to...
Low serum desnutrin predicts insulin resistance in patients with vitiligo vulgaris
Use of electric hair styling tools tied to burn injuries in children
Alpha-gal syndrome: Red meat allergy linked with tick
